BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average rating of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.00.

Several research firms have issued reports on BCRX. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Sunday, May 28th. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, March 1st. Finally, Jefferies Group LLC raised their target price on BioCryst Pharmaceuticals from $3.50 to $6.00 and gave the stock a “positive” rating in a research note on Tuesday, February 28th.

BioCryst Pharmaceuticals (NASDAQ BCRX) traded up 2.88% during trading on Monday, reaching $5.71. The company had a trading volume of 502,818 shares. The company’s 50-day moving average is $5.69 and its 200 day moving average is $6.48. BioCryst Pharmaceuticals has a 52 week low of $2.60 and a 52 week high of $9.25. The firm’s market capitalization is $459.20 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company had revenue of $9.40 million during the quarter, compared to analysts’ expectations of $6.13 million. BioCryst Pharmaceuticals had a negative return on equity of 323.86% and a negative net margin of 150.24%. The firm’s quarterly revenue was up 95.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals will post ($0.73) EPS for the current year.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after buying an additional 1,651,292 shares during the last quarter. RA Capital Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 16.7% in the first quarter. RA Capital Management LLC now owns 3,489,795 shares of the biotechnology company’s stock worth $29,314,000 after buying an additional 500,000 shares during the last quarter. State Street Corp boosted its stake in shares of BioCryst Pharmaceuticals by 8.6% in the first quarter. State Street Corp now owns 2,272,104 shares of the biotechnology company’s stock worth $19,083,000 after buying an additional 179,216 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of BioCryst Pharmaceuticals by 36.1% in the first quarter. Jennison Associates LLC now owns 1,844,636 shares of the biotechnology company’s stock worth $15,495,000 after buying an additional 489,536 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of BioCryst Pharmaceuticals by 97.5% in the first quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock worth $12,238,000 after buying an additional 719,162 shares during the last quarter. 84.45% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/19/biocryst-pharmaceuticals-inc-bcrx-receives-average-rating-of-buy-from-analysts.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.